Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab extension study for patients with solid tumors benefiting at the end of a Roche/Genentech parent trial
NL-OMON37844Phase 4Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in Nonhematologic neoplasms and cancer, sponsored by Roche. Primary endpoints: Continued bevacizumab access and Long-term bevacizumab safety. Started Oct 2012; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON37844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37844.